Mologen AG (MOLGF.PK): DSLIM® Shows Superior Immunoactivation Capabilities
4/8/2014 2:01:28 PM
Berlin, April 08, 2014 – MOLOGEN AG has presented latest research results on its immunomodulator and TLR9 agonist dSLIM® in a poster presentation at the American Association for Cancer Research (AACR) 2014 Meeting in San Diego. The results show that the unique conformation of MOLOGEN’s dSLIM® molecule leads to superior cancer-fighting immunoactivation compared to other TLR9 agonists.
DNA-based TLR9 agonists are potent activators of immune cell populations and the immune system. The poster presentation reported results from a comparison of dSLIM® with a different TLR9 agonist, representing the classes of TLR9 agonists with linear DNA molecules.
dSLIM® establishes a new class of TLR9 agonists, represented by covalently closed dumbbell-like DNA molecules consisting entirely of natural DNA components with two single-stranded CG-containing loops separated by a double-stranded stem. In contrast to dSLIM®, all known classes of TLR9 agonists are made of linear DNA molecules containing non-natural DNA modifications.
dSLIM® is the active ingredient of the drug candidate MGN1703 currently developed by MOLOGEN in oncology. In 2013 MGN1703 reported positive phase II data in colorectal cancer (CRC) and this year a phase III is planned in the same indication. Recently, a randomized study in small cell lung cancer started patient accrual.
Poster at the AACR-Meeting 2014 (poster abstract # 2565)
“Conformation overrides base sequence - insights from novel class TLR9 agonists” - Kerstin Kapp1, Matthias Schroff1, Burghardt Wittig2, Christiane Kleuss1 (1Mologen AG, Berlin, Germany, 2Foundation Institute Molecular Biology and Bioinformatics, Freie Universität Berlin, Germany)
MGN1703 is based on dSLIM® (“double Stem Loop Immunomodulator”), an innovative DNA-based TLR9 agonist developed by MOLOGEN. dSLIM® activates the immune system against tumor-associated antigens by targeting various receptors on certain immune cells, primarily TLR9. Tumor-associated antigens (TAA) are released by cancer cells as a result of chemotherapy and radiation therapy. Once activated by dSLIM®, the immune system is able to overcome its fatal tolerance toward cancer cells and TAA and attacks them selectively. Due to this mechanism of action, MGN1703 can be applied to different indications of cancer.
About MOLOGEN AG
MOLOGEN AG is a publicly listed biotechnology company headquartered in Berlin and specializes in the research and clinical development of innovative drugs in the fields of oncology and infectious diseases. One of the company’s most important product candidates is the DNA immunomodulator MGN1703, which is being clinically developed for colorectal cancer and lung cancer. The cell-based cancer therapy MGN1601 for the treatment of renal cancer is also currently at the stage of clinical development.
With unique, patented technologies and innovative product developments, MOLOGEN is one of the leading biotechnology companies in the fields of DNA medicine and cell-based therapies.
MOLOGEN AG shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange.
Help employers find you! Check out all the jobs and post your resume.
comments powered by